SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
- Author:
Huitzilihuitl SAUCEDO-OROZCO
1
;
Suzanne N. VOORRIPS
;
Salva R. YURISTA
;
Rudolf A. DE BOER
;
B. Daan WESTENBRINK
Author Information
- Publication Type:Review
- From:Journal of Lipid and Atherosclerosis 2022;11(1):1-19
- CountryRepublic of Korea
- Language:English
- Abstract: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence or absence of type 2 diabetes. While the mechanisms underlying the salutary effects of SGLT2 inhibitors have not been fully elucidated, there is clear evidence for a beneficial metabolic effect of these drugs. In this review, we discuss the effects of SGLT2 inhibitors on cardiac energy provision secondary to ketone bodies, pathological ventricular remodeling, and inflammation in patients with HF. While the specific contribution of ketone bodies to the pleiotropic cardiovascular benefits of SGLT2 inhibitors requires further clarification, ketone bodies themselves may also be used as a therapy for HF.
